good news for those bought at $1-$2 but bad news for those bought at $20+
Now the stock is less risk and less award.
1. With Takeda taking full responsibility for OMONTYS, the drug will be back to market at very very chance (Note: a proved drug with 99.8% effective already). It is much less risk and the stock price should be $2-$3 before re-introducing and $5-$15 after re-introducing.
2. Because Takeda receives a worldwide, exclusive royalty-bearing license under Affymax and joint Takeda-Affymax patents to develop, manufacture and commercialize OMONTYS, Affymax get less profit after re-introducing. The stock price won't reach $25-$80 range.
3. Takeda may know the root-cause already but want to fully control OMONTYS and Affymax may ...